Erica Golemis, PhD


Research Program

Mammary tumor formation analysis shows absence of NEDD9 decreases tumor incidence.
Figure 2
Figure 3.
Figure 4.


Education and Training

Educational Background

  • Post-Doctoral Studies, (yeast biotechnology/development of a two-hybrid system) , Massachusetts General Hospital Department of Molecular Biology and Harvard Medical School Department of Genetics, 1993
  • PhD, Biology (focus: murine retroviruses and leukemogenesis), Massachusetts Institute of Technology, 1988
  • BA, Biology and English, Bryn Mawr College, 1983


    • Member, American Society for Cell Biology
    • Member, American Association for Cancer Research
    • Member, American Association for the Advancement of Science
    Research Profile

    Research Program

    Research Facility

    Research Interests

    Targeting signaling networks to improve therapy

    • The molecular basis for resistance to targeted anti-cancer agents
    • Interactions of the oncogenes NEDD9 and Aurora-A kinase in cancer and polycystic kidney disease.
    • Targeting HSP90 to improve therapy: new strategies.
    • Defining the underlying basis for cancer risk.

    Lab Overview

    In disease states such as cancer, tumors reprogram their signaling to support abnormal growth processes. Our laboratory is interested in defining the changes in cell signaling that occur as tumors initiate, progress, and develop resistance to drugs, with the ultimate goal of inhibiting these processes. We hope through these studies to better define the interactions of signaling pathways in malignant versus normal cells, allowing improvements in cancer diagnosis and treatment. In specific projects, our work divides between a body of translational studies focused on the optimal use of therapeutic drugs, and more basic investigations into fundamental cell signaling mechanisms.  

    In the area of translational studies, we have been exploring the use of HSP90-targeting inhibitors in two ways. Gaponova, Nikonova, Deneka, and Feng have been evaluating the use of novel HSP90-targeted cytotoxic agents for efficacy in small cell lung cancer, a disease with few therapeutic options. Beck and Korobeynikov have used high throughput RNA interference screening to identify genes that regulate response to the HSP90 inhibitor ganetespib. Nikonova has also been investigating the use of HSP90 inhibitors and other targeted cancer agents in autosomal dominant polycystic kidney disease (ADPKD), that conserves many features of cancer. Arora is investigating the hereditary basis for undiagnosed familial gastrointestinal and genitourinary tumors.  Members of the laboratory, led by Serebriiskii, actively collaborate with numerous clinical investigators at Fox Chase Cancer Center, on topics including definition of biomarkers for cancer risk and therapeutic response, and mechanisms of resistance to targeted inhibitors of EGFR, Aurora-A, Src, and other proteins relevant to the core interests of the laboratory.  

    Increasingly, these studies incorporate analysis of underlying genetic features of tumors, through use of next generation sequencing and bioinformatic interpretation. As basic research projects, Nikonova, Deneka, and Kopp studies the activity of a signaling scaffold, NEDD9, and interacting proteins such as the oncogenic kinase Aurora-A, to understand the requirement for their action in normal cells, lung cancer, and in ADPKD. With Korobeynikov, and as an area of emphasis, these investigators study regulation of the cell cilium, an organelle that coordinates receipt of extracellular signals related to fluid flow and the Hedgehog, Wnt, and other signaling systems, and which is regulated by NEDD9 and Aurora-A signaling.

    Extramural Affiliations
    • Adjunct, Cell and Molecular Biology group, University of Pennsylvania
    • Adjunct, Department of Biochemistry, Drexel University School of Medicine
    • Adjunct, Department of Biochemistry, Lewis Katz School of Medicine, Temple University
    Lab Staff

    Ilya Serebriiskii, PhD

    Assistant Professor

    Room: W406

    Anna S. Nikovona, PhD

    Research Associate

    Room: W406

    Alexander Deneka, MD

    Postdoctoral Fellow

    Room: W406

    Anna Kiseleva, MS

    Graduate Student

    Room: W406

    Leonid Kharin

    Postdoc Associate

    Room: W406

    Mitchell Parker

    MD. PhD Student, Drexel University College of Medicine

    Room: W406

    Danlin Sun

    Graduate Student, Jiangsu University

    Room: W406

    Additional Staff

    Student Assistants and Volunteers

    Rahmat Sykder, volunteer

    Laboratory Alumni/ae

    Sanjeevani Arora, PhD - postdoc

    Tim Beck - grad student

    Margret B. Einarson, PhD - postdoc

    Sarah Fashena, PhD - postdoc

    Yayi Feng - grad student

    Anna Gaponova - grad student

    Eugene Izumchenko, PhD - grad student

    Vladimir Khazak, PhD - postdoc

    Meghan Kopp - grad student

    Vlad Korobeynikov - grad student

    Susan Law, PhD - postdoc

    Joy L. Little, PhD - postdoc

    Hanqing Liu, PhD - postdoc

    Rochelle Nasto, PhD - grad student

    Geraldine M. O'Neill, PhD - postdoc

    Olga V. Plotnikova, PhD - grad student

    Elena N. Pugacheva, PhD - postdoc

    Vladimir Ratushny, MD, PhD - grad student

    Tamina Seeger-Nukpezah, MD, PhD - postdoc

    Victoria Serzhanova - Graduate Student

    Natalya Skobeleva, MD, PhD - Research Associate

    Nadezhda (Nadya) Tikhmyanova, PhD - grad student

    Garabet Toby, PhD - grad student

    Peishan Zhang, BS

    Yu-Zhu Zhang, PhD - postdoc

    Former Lab Staff

    Wahiba Gherraby, scientific technician

    Former Student Volunteers

    Rihua Chen, volunteer

    Adaeze Chikwem, volunteer

    Christiaan Honig, Volunteer, Germantown Academy, Fort Washington, PA

    Sammi Hurley, Volunteer, University of Michigan, Ann Arbor, MI

    Brook Neumann, volunteer

    Katherine Xu, volunteer

    Jennifer Cracchiolo, Temple University School of Medicine

    Nicolas G. Day, Student Assistant, St. John's College, Annapolis, MD

    Sanat Deshpande, Wissahickon Senior High School

    Louisa Eckman, Haverford College

    Rachel Georgopoulos, Temple University School of Medicine

    Timothy Kistner, Student Assistant

    Rabuil Ryan, Student Assistant

    David Sarcu, Temple University School of Medicine

    Manali Shah, Student Assistant

    Shelly Singh, University of Pittsburgh

    Zachary Smithline, Volunteer, Council Rock High School, Council Rock, PA

    Zachary Wells, Student Assistant, Liberty College, Lynchburg, VA

    Cecilia Zemanek, Student Assistant


    Selected Publications

    Nicolas E, Tricarico R, Savage M, Golemis EA, Hall MJ. Disease-Associated Genetic Variation in Human Mitochondrial Protein Import. American Journal of Human Genetics, 2019. PubMed

    Golemis EA, Scheet P, Beck TN, Scolnick EM, Hunter DJ, Hawk E, Hopkins N. Molecular mechanisms of the preventable causes of cancer in the United States. Genes & development, 32(13-14):868-902, 2018. PMC6075032

    Gabbasov R, Xiao F, Howe CG, Bickel LE, O'Brien SW, Benrubi D, Do TV, Zhou Y, Nicolas E, Cai KQ, Litwin S, Seo S, Golemis EA, Connolly DC. NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene, 2018. PubMed

    Golemis EA, Scheet P, Beck TN, Scolnick E, Hunter DJ, Hawk E, Hopkins N. Molecular mechanisms of the preventable causes of cancer in the United States. Genes & Development, 2018.

    Liu H, Kiseleva AA, Golemis EA. Ciliary signalling in cancer. Nature Reviews Cancer, 2018.

    Nikonova AS, Deneka AY, Kiseleva AA, Korobeynikov V, Gaponova A, Serebriiskii IG, Kopp MC, Hensley HH, Seeger-Nukpezah TN, Somlo S, Proia DA, Golemis EA. Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 32(5):2735-46, 2018. PMC5901382

    Nikonova AS, Deneka AY, Kiseleva AA, Korobeynikov V, Gaponova A, Serebriiskii IG, Kopp MC, Hensley HH, Seeger-Nukpezah TN, Somlo S, Proia DA, Golemis EA. Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). Faseb j:fj201700909R, 2018.

    Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun, 8(1):1772, 2017. PMC5701248

    Gaponova, A.V., Deneka, A.Y., Beck, T.N., Liu, H., Andrianov, G., Nikonova, A.S., Nicolas, E., Einarson, M.B., Golemis, E.A., and Serebriiski, I.G., Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin. Oncotarget 8(12):19156-19171, 2017.

    Franco-Barraza, J., Francescone, R., Luong, T., Shah, N., Madhani, R., Gukierman, G., Malik, R., Dulaimi, E., Devarajan, K., Egleston, B.L., Nicolas, E., Alpaugh, R.K., Uzzo, R.G., Hoffman, J.P., Golemis, E.A., and Cukierman, E. Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence. Elife 6:e20600, 2017.

    Peri, S., Izumchenko, E., Schubert, A.D., Slifker, M.J., Ruth, K., Serebriiskii, I.G., Guo, T., Burtness, B.A., Mehra, R., Ross, E.A., Sidransky, D., and Golemis, E.A. NSD1- and NSD2-damaging mutations defina subset of laryngeal tumors with favorable prognosis. Nat Commun, 2017 Nov 24;8(1):1772.

    Kudinov, A.E., Karanicolas, J., Golemis, E.A., and Boumber, Y. Musashi RNA-binding proteins as drivers and novel therapeutic targets in cancer. Clin Cancer Res, Epub Jan 31 2017.

    Korobeynikov, V., Deneka, A.Y., and Golemis, E.A. Mechanisms for non-mitotic activation of Aurora-A at cilia, Biochem Soc Trans 45:37-49, 2017.

    Kudinov, A., Deneka, A., Nikonova, A.S., Beck, T.N., Ahn, Y.-H., Liu, X., Martinez, C.F., Schultz, F.A., Reynolds, S., Yang, D.-H., Cai, K.Q. Yaghmour, K.M., Baker, K.A., Egleston, B. L, Nicolas, E., Chikwem, A., Andrianov, G., Singh. S., Borghaei, H., Serebriiskii, I.G., Gibbons, D.L., Kurie, J.M., Golemis, E.A., and Boumber, Y. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.  PNAS, 113(25):6955-60, 2016, PMID:27274057.

    Gaponova, A.V., Nikonova, A., Deneka, A.Y., Kopp, M.C., Kudinov, A.E., Skobeleva, N., Khazak, V., Shin Ogawa, L., Cai, K.Q., Duncan, K.E., Duncan, J.S., Egleston, B.L., Proia, D.A., Boumber, Y., Golemis, E.A. A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC). Clin Cancer Res. 22:5120-29, 2016. PMID: 27267850.

    Additional Publications

    My NCBI

    This Fox Chase professor participates in the Undergraduate Summer Research Fellowship
    Learn more about Research Volunteering.

    Connect with Fox Chase